Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes - Trial NCT05620251
Access comprehensive clinical trial information for NCT05620251 through Pure Global AI's free database. This phase not specified trial is sponsored by Istanbul Medeniyet University and is currently Completed. The study focuses on type1diabetes. Target enrollment is 121 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Istanbul Medeniyet University
Timeline & Enrollment
N/A
Sep 03, 2021
Jun 12, 2022
Primary Outcome
humoral immune response after first vaccine dose,humoral immune response after second vaccine dose
Summary
Adolescents with type 1 diabetes may be at increased risk for severe coronavirus disease-2019
 (COVID-19) and are therefore prioritized for access to severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV-2) vaccination. The pivotal trial that assessed the efficacy of the
 BNT162b2 vaccine among adolescents demonstrated 100% protection against SARS-CoV-2 infection
 after a two-dose regimen. However, the research did not include adolescents with type 1
 diabetes. In this study, the investigators aimed to assess the humoral immune response of
 infection-naive adolescents with type 1 diabetes following vaccination with the BNT162b2
 vaccine in comparison to that of infection-naive healthy controls and the factors associated
 with that response.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05620251
Non-Device Trial